Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases.

Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia.

In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form Valneva.

In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.

[5][6] Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.